Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. The Company is focused on new product candidates and platforms to expand its pipeline based on a deep understanding of immunotherapies and its license agreements with University of California San Diego.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/10/26	US$0.1368	-44.99%	607
27/10/26	US$0.2487	+38.17%	500
26/10/26	US$0.1800	+200.00%	285

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 16:26:22 28/10/2026 GMT			5-day change	1st Jan Change
0.1368 ^USD	-44.99%		+128.00%	-56.01%

08-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	991K 887K 816K 740K 1.38M 94.07M 1.41M 9.73M 3.91M 49.48M 3.72M 3.64M 156M	P/E 2024	-5.39x	P/E 2025	-3.11x
Enterprise Value	2.65M 2.38M 2.19M 1.98M 3.7M 252M 3.77M 26.06M 10.46M 133M 9.96M 9.74M 418M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	11.32%	Yield 2024 *	-	Yield 2025	-

08-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-19	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
19/08/25	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
20/05/25	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
15/04/25	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
14/04/25	Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt	CI
19/11/24	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/08/24	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
25/07/24	Mosaic ImmunoEngineering, Inc. Announces Resignation of Carlton Johnson from the Board, the Audit Committee and Compensation Committee	CI
14/05/24	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

29/04/24	Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	AQ
28/03/24	Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K	PU
03/05/23	MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)	AQ
02/03/23	MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
01/11/22	MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Mosaic ImmunoEngineering, Inc. Share Price

Stocks

CPMV

US61945M1018

Biotechnology & Medical Research

Valuation: Mosaic ImmunoEngineering, Inc.

Chart: Mosaic ImmunoEngineering, Inc.

Latest news: Mosaic ImmunoEngineering, Inc.

Press Releases: Mosaic ImmunoEngineering, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Mosaic ImmunoEngineering, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-44.99%
1 week	+128.00%
1 month	+124.26%
3 months	+128.00%
6 months	-81.65%
Current year	-56.01%

1 week	0.14	0.25
1 month	0.06	0.33
Current year	0.05	0.75
1 year	0.05	0.89
3 years	0.05	1.13
5 years	0.05	3
10 years	0.05	9.22

Date	Insider	Type	Main position	% Market Cap.
18/02/22	Robert Garnick	Others	Founder	0%
18/02/22	Steven King	Others	Chief Executive Officer	0%
18/02/22	Robert Baffi	Others	Director	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MOSAIC IMMUNOENGINEERING, INC.	-44.99%	+128.00%	-83.67%	-76.00%	991K
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	-4.19%	+6.79%	+34.45%	+167.89%	39.43B
Weighted average by Cap.	+0.18%	+5.44%	+47.99%	+176.67%

	2024	2025
Net sales	-	-
Net income	-922K -826K -760K -688K -1.29M -87.54M -1.31M -9.06M -3.64M -46.05M -3.46M -3.39M -145M	-688K -616K -567K -513K -960K -65.31M -978K -6.76M -2.71M -34.36M -2.58M -2.53M -108M
Net Debt	1.48M 1.32M 1.22M 1.1M 2.06M 140M 2.1M 14.52M 5.83M 73.8M 5.54M 5.43M 233M	1.66M 1.49M 1.37M 1.24M 2.32M 158M 2.36M 16.33M 6.56M 83.02M 6.24M 6.11M 262M